Cargando…
Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy
Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in both newly diagnosed and relapsing patients. However, the role of RTX in the management of the most severe ca...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988143/ https://www.ncbi.nlm.nih.gov/pubmed/35401565 http://dx.doi.org/10.3389/fimmu.2022.777134 |
_version_ | 1784682897818517504 |
---|---|
author | Roccatello, Dario Sciascia, Savino Murgia, Stefano Quattrocchio, Giacomo Ferro, Michela De Simone, Emanuele Naretto, Carla Barreca, Antonella Sammartino, Andrea Rossi, Daniela Fenoglio, Roberta |
author_facet | Roccatello, Dario Sciascia, Savino Murgia, Stefano Quattrocchio, Giacomo Ferro, Michela De Simone, Emanuele Naretto, Carla Barreca, Antonella Sammartino, Andrea Rossi, Daniela Fenoglio, Roberta |
author_sort | Roccatello, Dario |
collection | PubMed |
description | Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in both newly diagnosed and relapsing patients. However, the role of RTX in the management of the most severe cases of AAV remains to be fully elucidated. The aim of this study was to assess both safety and efficacy of an intensified B-cell depletion therapy (IBCDT) protocol, including RTX, cyclophosphamide (CYC), and methylprednisolone pulses without additional maintenance immunosuppressive therapy in a cohort of 15 AAV patients with the most severe features of AVV renal involvement (as <15 ml/min GFR and histological findings of paucimmune necrotizing glomerulonephritis with more than 50% crescents of non-sclerotic glomeruli at the renal biopsy). Results of the IBCDT regimen have been compared to those obtained in a control cohort of 10 patients with AAV treated with a conventional therapy regimen based on oral CYC and steroids followed by a prolonged maintenance therapy with azathioprine (AZA). Plasma exchange was equally employed in the study and the control group. Complete clinical remission (BVAS 0) was observed at 6 months in 14 of 15 patients treated with IBCDT (93%). All cases who achieved a complete clinical remission experienced a depletion of peripheral blood B cells at the end of therapy. Of the 10 dialysis dependent patients at onset, 6 subjects (60%) experienced a functional recovery allowing the suspension of dialysis treatment. When compared to the control group, no statistically significant difference was observed in patients treated with IBCDT in terms of overall survival, 6-month therapeutic response rate, and 6-, and 12-month functional renal recovery. The cumulative total dose of CYC in the case group was on average 1 g/patient while in the control group on average 8.5 g/patient (p = 0.00008). Despite the retrospective design and relative limited sample size, IBCDT appeared to be safe and had the same efficacy profile when compared to the conventional therapy with CYC plus AZA in the management of the most severe patients with AAV. Additionally, this avoided the need of prolonged maintenance therapy for long, and limited the exposure to CYC with consequent reduced toxicity and drug-related side effect rates. |
format | Online Article Text |
id | pubmed-8988143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89881432022-04-08 Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy Roccatello, Dario Sciascia, Savino Murgia, Stefano Quattrocchio, Giacomo Ferro, Michela De Simone, Emanuele Naretto, Carla Barreca, Antonella Sammartino, Andrea Rossi, Daniela Fenoglio, Roberta Front Immunol Immunology Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in both newly diagnosed and relapsing patients. However, the role of RTX in the management of the most severe cases of AAV remains to be fully elucidated. The aim of this study was to assess both safety and efficacy of an intensified B-cell depletion therapy (IBCDT) protocol, including RTX, cyclophosphamide (CYC), and methylprednisolone pulses without additional maintenance immunosuppressive therapy in a cohort of 15 AAV patients with the most severe features of AVV renal involvement (as <15 ml/min GFR and histological findings of paucimmune necrotizing glomerulonephritis with more than 50% crescents of non-sclerotic glomeruli at the renal biopsy). Results of the IBCDT regimen have been compared to those obtained in a control cohort of 10 patients with AAV treated with a conventional therapy regimen based on oral CYC and steroids followed by a prolonged maintenance therapy with azathioprine (AZA). Plasma exchange was equally employed in the study and the control group. Complete clinical remission (BVAS 0) was observed at 6 months in 14 of 15 patients treated with IBCDT (93%). All cases who achieved a complete clinical remission experienced a depletion of peripheral blood B cells at the end of therapy. Of the 10 dialysis dependent patients at onset, 6 subjects (60%) experienced a functional recovery allowing the suspension of dialysis treatment. When compared to the control group, no statistically significant difference was observed in patients treated with IBCDT in terms of overall survival, 6-month therapeutic response rate, and 6-, and 12-month functional renal recovery. The cumulative total dose of CYC in the case group was on average 1 g/patient while in the control group on average 8.5 g/patient (p = 0.00008). Despite the retrospective design and relative limited sample size, IBCDT appeared to be safe and had the same efficacy profile when compared to the conventional therapy with CYC plus AZA in the management of the most severe patients with AAV. Additionally, this avoided the need of prolonged maintenance therapy for long, and limited the exposure to CYC with consequent reduced toxicity and drug-related side effect rates. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8988143/ /pubmed/35401565 http://dx.doi.org/10.3389/fimmu.2022.777134 Text en Copyright © 2022 Roccatello, Sciascia, Murgia, Quattrocchio, Ferro, De Simone, Naretto, Barreca, Sammartino, Rossi and Fenoglio https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Roccatello, Dario Sciascia, Savino Murgia, Stefano Quattrocchio, Giacomo Ferro, Michela De Simone, Emanuele Naretto, Carla Barreca, Antonella Sammartino, Andrea Rossi, Daniela Fenoglio, Roberta Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy |
title | Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy |
title_full | Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy |
title_fullStr | Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy |
title_full_unstemmed | Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy |
title_short | Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy |
title_sort | treating patients with anca-associated vasculitis and very severe renal injury with an intensified b cell depletion therapy: comparison with a control cohort receiving a conventional therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988143/ https://www.ncbi.nlm.nih.gov/pubmed/35401565 http://dx.doi.org/10.3389/fimmu.2022.777134 |
work_keys_str_mv | AT roccatellodario treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT sciasciasavino treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT murgiastefano treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT quattrocchiogiacomo treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT ferromichela treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT desimoneemanuele treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT narettocarla treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT barrecaantonella treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT sammartinoandrea treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT rossidaniela treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy AT fenoglioroberta treatingpatientswithancaassociatedvasculitisandverysevererenalinjurywithanintensifiedbcelldepletiontherapycomparisonwithacontrolcohortreceivingaconventionaltherapy |